INTRODUCTION {#S1}
============

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for many patients with hematological diseases. Success of HCT relies greatly on accurate pre-transplant risk-assessment. The HCT-comorbidity index (CI) was developed as a measure of health-status that could quantify the magnitude of organ dysfunctions before and could stratify mortality risk following HCT ([@R1]). Further, information is required to determine the underlying association between biologic tissue-specific processes related to comorbidities and post-transplant mortality. Such biological processes could serve as novel biomarkers that could improve pre-HCT comorbidity screening and improve the prognostic power for post-HCT mortality.

Here, we analyzed in a preliminary study plasma micro-RNAs (miRs) as a novel and potentially powerful biomarker approach for prediction of HCT outcomes. MiRs are a class of small non-coding RNAs (\~22 nt) that negatively regulate gene expression by pairing with partially complementary target sequences in the 3' untranslated regions of messenger RNAs (mRNAs) to block translation and/or promote mRNA degradation ([@R2]). They control activity of \~30% of all protein-coding genes with an average of \~200 mRNA targets per miR molecule ([@R3]). A series of studies has uncovered the functional role of miRs in diverse biological and pathophysiological processes including cardiac, vascular, hepatic ([@R4]), and autoimmune diseases ([@R5]).

Recent discoveries suggested a strong role of miR-423, miR-199a-3p, miR-93\*, and miR-377, miR-146a, and miR-155 in predicting probability of acute graft versus-host disease (GVHD) ([@R6]--[@R9]). However, these miRs were evaluated after HCT, which limits the ability to use them in pre-transplant decision making. To date, no dedicated analysis of associations between pre-transplant miRs and mortality has been done. To this end, we took an initial step in this process, as a proof of concept, by examining associations between pre-transplant miRs, comorbidities, and post-transplant mortality.

SUBJECTS AND METHODS {#S2}
====================

Subjects {#S3}
--------

Informed consent was collected from patients at the time of donation of their blood sample for research purposes. Because this is a retrospective study, no new consent form was collected. The study was approved by the Fred Hutchinson Cancer Research Center Internal Review Board (IRB).

Study participants had the following criteria 1) diagnosis of acute myeloid (AML) or lymphoid (ALL) leukemia, 2) were in complete remission before HCT, 3) received HLA-matched peripheral blood mononuclear cell (PBMC) grafts, 4) had PBMC previously collected and stored within 30 days prior to HCT, and 5) treated with allogeneic HCT between 2005 and 2009. Of the 140 patients that met these criteria, 36 were randomly selected that met one of two other criteria: had pre-transplant HCT-CI scores of 0 and survived HCT per last-follow up (low-risk, n=18) or had HCT-CI scores of ≥4 and died after HCT (high-risk, n=18). Comorbidities were scored per the HCT-CI ([@R1], [@R10]). We collected information on causes of death (COD) as stratified into: root COD defined as the underlying cause, contributing COD defined as other ongoing problems leading to and contributing to death, and proximate COD defined as the most significant recent cause to deterioration of patient health before death.

MiR Analysis {#S4}
------------

All samples were collected in ethylenediaminetetraacetic (EDTA) acid tubes and processed and frozen at −80 ^o^C within 8 hours of draw. RNA was isolated from PBMC per previous methods ([@R11]). For discovery of potentially relevant miRs, we used the NanoString nCounter miR assay as previously described ([@R12]). Analysis of miR raw data was done using nSolverTM 2.0 Software (NanoString Technologies, Inc.) applying standard quality control tests.

Overview of Nanostring Methodology {#S5}
----------------------------------

To develop and optimize a clinically relevant method for the identification of novel biomarkers for relevant comorbidities before and prognostic biomarkers for mortality after HCT, we utilized an assay based on the recently described NanoString multiplex platform (nCounter) incorporating fluorescent barcodes together with a digital readout for single-molecule imaging ([@R13]). In contrast to other miR profiling technologies, the NanoString platform does not involve reverse transcription; instead the technology relies on sequence-specific probes to digitally measure the copy number (DNA), target (i.e., mRNA), or small RNA (e.g. mature miR) abundance. Through the use of a chimeric mature miR-miRTag sequence, the nCounter miR assays can therefore accurately distinguish between highly homologous miR family members with great specificity, without the need for enzymatic amplification ([@R14]). The NanoString miR pre-designed panel simultaneously detects 673 human miRs including five housekeeping transcripts \[(actin beta (NM_001101.2), beta-2 microglobulin (NM_004048.2), GAPDH (NM_002046.3), RPL19 (NM_000981.3), and RPLP0 (NM_001002.3)\], six positive, and eight negative controls (proprietary spike-in controls to determine sample integrity as well as efficiency and background).

Each human miR of interest is detected using a specific pair of probes called the reporter and capture probes. Each probe within a probe pair contains miR-specific sequences that together recognize a 100-base contiguous region within the targeted miR. In addition, the reporter probes carry a color code at the 5' end that enables the molecular barcoding of the miRs of interest, while the capture probes carry a biotin label at the 3' end that provides a molecular handle for the attachment of target genes to facilitate downstream digital detection. The color code on each reporter probe has six positions, each of which can be one of four spectrally non-overlapping fluorescent colors. The different combinations of the four distinct colors at six contiguous positions allows for a large diversity of color-based barcodes, each designating a different mature miR sequence that can be mixed together in a single reaction for hybridization and still be individually resolved and identified. This allows a large diversity of targets present in the same sample to be individually resolved and identified during data collection. It is theoretically possible to generate 46 different color codes, each barcoding a distinct small RNA. However, the kinetics of solution-phase hybridization and the technology for digital detection of different color barcodes currently limit the measurement power to less than a thousand miR species.

Methodology {#S6}
-----------

### RNA extraction. {#S7}

The use of control RNA included in the nCounter Human miR Sample Preparation Kit allows the user to monitor the ligation efficiency and specificity through each step of the reaction, thereby serving as a control for integrity and quality of the total RNA as well as the purified miR samples. Recovery of these 6 different synthetic miRs also provides confidence that that the Nanostring nCounter system performs as expected.

### miR expression profiling. {#S8}

The digital multiplexed NanoString nCounter human miR expression assay (NanoString Technologies) was performed with 100 ng total RNA as input material according to the NanoString miR Assay Manual. Small RNA samples were prepared by ligating a specific DNA tag (miR-tag) onto the 3' end of each mature miR according to the manufacturer's instructions (NanoString Technologies). These tags serve several purposes: 1) to normalize the wide range of melting temperatures (Tms) of the miRs; 2) to provide a template to facilitate the use the NanoString dual probe system; 3) to enable single base pair discrimination and specificity of highly homologous miR family members; and 4) to provide identification for each miR species in the sample. Excess tags were then removed with the use of a restriction digest at 37^o^C. The resulting material was incorporated into an overnight hybridization reaction. Hybridizations were carried out by combining 5 µl of each miR-miRTag sample with 20 µl of nCounter Reporter probes in hybridization buffer and 5 µl of nCounter Capture probes for a total reaction volume of 30 µl. The hybridizations were incubated at 65°C for approximately 16 to 20 hours. During the overnight hybridization reaction, probe pairs are present in large excess to target small RNAs to ensure that each target finds a probe pair.

### Overview of thermocycling conditions. {#S9}

The nCounter miR Preparation protocol requires careful temperature control of all reaction steps. A thermocycler with a heated lid is critical for this procedure.

#### Annealing Protocol {#S10}

Temperature Time

94°C 1 min

65°C 2 min

45°C 10 min

48°C hold

Total Time 13 min

#### Ligation Protocol {#S11}

Temperature Time

48°C 3 min

47°C 3 min

46°C 3 min

45°C 5 min

65°C 10 min

4°C hold

Total Time 24 min

#### Purification Protocol {#S12}

Temperature Time

37°C 2 hours

70°C 10 min

4°C hold

Total Time 2 hours 10 min

### nCounter Prep station. {#S13}

The nCounter Prep Station is the automated fluidic handling component of the nCounter System and processes samples post-hybridization to prepare them for data collection on the nCounter Digital Analyzer. Excess probes are washed away using a two-step magnetic bead based purification on the nCounter Prep Station. Magnetic beads derivatized with short nucleic acid sequences that are complementary to the Capture Probe and the Reporter Probes are used. First, the hybridization mixture containing target/probe complexes is allowed to bind to magnetic beads complementary to sequences on the Capture Probe and washed followed by a sequential binding to sequences on the Reporter Probe. Biotinylated capture probe-bound miR-miRtags are immobilized and recovered on a streptavidin-coated cartridge using the nCounter PrepStation (nanoString Technologies). Abundances of specific miR molecules can then be quantified using the nCounter Digital Analyzer to count the individual fluorescent barcodes and assess target miR molecules present in each sample. For each assay, a high-density scan (encompassing 600 fields of view) was performed.

### nCounter Digital Analyzer. {#S14}

The nCounter Digital Analyzer collects data by taking images of the immobilized fluorescent reporters in the sample cartridge with a CCD camera through a microscope objective lens. At the highest standard data resolution, 600 fields of view (FOV) are collected per flow cell (sample), yielding data of hundreds of thousands of target molecule counts. The number of images taken corresponds to the number of reporters counted and this, in part, determines the dynamic range and level of sensitivity in the system. Images are processed internally, and the results are exported as a comma-separated values format file that can be downloaded via memory stick. The file can be opened by most commonly used spreadsheet packages, including Microsoft® Excel, exported to other data visualization packages, or normalized using the NanoString nSolver software analysis tool.

Data Analysis and Statistical Methods {#S15}
-------------------------------------

All data analysis was performed using the nSolver software analysis (freely available for download from NanoString Technologies). A comprehensive manual outlining all strategies for data analysis and normalization of miR data accompanies the use of the software tool. Heat maps were created to show median-centered expression of each gene using Cluster 3.0 and JavaTreeView software algorithms applied to log2 transformed data.

All samples contributed to the discovery analysis. MiRs were filtered to include only those expressed with at least 50 counts for the NanoString abundance analyses. MiR raw data was normalized using the geometric mean of top 100 miRs (probes with highest 100 counts) as recommended by the manufacturer. Fold-change was calculated with partitioning by the low- versus high-risk groups computing a two-tailed t-test on the log-transformed normalized data that assumes unequal variance. We used a p-value cut-off of \<0.1 to identify potentially relevant miRs. Heat-map analysis used z-score transformation on samples computing Spearman correlation of the medians between two samples of 8 patients from each group.

We then compared the mean expression level between low- and high-risk patients for each of the 19 miRs identified from the initial examination using linear regression with adjustment for diagnosis, conditioning intensity, donor type, age (continuous variable), gender, and race. All p-values from regression models are two-sided.

We also fit multivariable logistic regression models (with the same adjustments as listed above) for the outcome high risk vs. low risk with miR expression as an exploratory variable. This effectively is the same model as the linear regression models above with miR expression as the outcome, but the logistic regression models allow one to estimate the area under the curve (AUC) associated with each miR in terms of separation of expression level between the two risk groups. An optimal expression cutoff for each miR was then estimated by maximizing Youden's J index (which corresponds to the threshold leading to the point on the receiver operating characteristic (ROC) curve that maximizes the vertical distance between the ROC curve and the non-informative diagonal line), and the associated odds ratio for expression levels above the appropriate threshold vs. expression levels below the threshold was estimated for the outcome defining risk (low risk vs. high risk).

With 18 patients in each of the risk groups, we have 85% power to observe a statistically significant difference (at the two-sided significance level of .05) in mean expression levels if the true distributions are separated by one standard-deviation unit.

Finally, even though the study was designed to look only at associations between miRs and mortality, we examined whether any of detected miRs is associated with development of grades II-IV or III-IV acute GVHD. This was done using multivariate regression models treating miRs as continuous variables.

RESULTS {#S16}
=======

Patient Characteristics {#S17}
-----------------------

Overall patient characteristics are summarized in [Table 1](#T1){ref-type="table"}. HLA-matched unrelated grafts were given to 83% and 72% of the low- and high-risk groups, respectively, while remaining patients received HLA-identical-sibling grafts. Diagnoses were AML in 78% and 67%, respectively, while remaining diagnoses were ALL. The majority of patients were in first CR (67% and 61%, respectively), while remaining patients were in second CR. Finally, 50% and 39% of patients, respectively, received high-dose conditioning regimens, while remaining patients received reduced-intensity regimens.

Cause of Death {#S18}
--------------

There were multiple COD for the 18 high-risk patients with increased expressions of the 8 miRs. Six patients (33.3%) had multiple organ failure with or without infections and acute GVHD. Five patients (27.8%) died from acute GVHD alone or coupled with cardiac complications such as heart failure. Four other patients (22.2%) died from infections alone or with heart or respiratory failures. Two patients died from cerebro-vascular strokes. One patient died from idiopathic pneumonia syndrome and respiratory failure.

Analysis of miRs expression among high vs. low risk groups {#S19}
----------------------------------------------------------

Among 654 tested miRs, 19 met the pre-specified significance level of *p*\<0.1. Among those 19 miRs, 7 were under-expressed, while 12 miRs were over-expressed before HCT among high- versus low-risk groups, respectively ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). In linear regression models for each of these 19 miRs, only 8 maintained statistically significant (*p* ≤ .05) differences between the two risk groups after adjustment for the factors defined under "Methods" above. Of the eight miRs, 2 were under-expressed \[miR-374b (*p* = 0.03), miR-454 (*p* = 0.04)\] and 6 were over-expressed \[miR-142--3p (*p*=.05), miR-191 (p = 0.02), miR-424 (p = 0.04), miR-590--3p (p = 0.03), miR-29c (p=.03), and miR-15b (p = 0.05)\] among high- versus low-risk groups as summarized in [Table 3](#T3){ref-type="table"}.

AUC results for these 8 miRs ranged between 0.74 to 0.81 ([Table 3](#T3){ref-type="table"}). Odds ratios for low-risk assignment when comparing patients with low (below the "optimal" threshold as defined above) vs. high (above the optimal threshold) expression ranged between 0 (eight of 8 low-expression patients were in low-risk category compared to 10 of 28 high-expression patients) and infinity (seven of 7 high-expression patients were in low-risk category compared to 11 of 29 low-expression patients).

In separate multivariate models where the 8 miRs were modeled as continuous variables, we found miR-15b (Odds ratio: 1.0005, p=0.03) and miR-191 (Odds ratio: 1.002, p=0.04) to be associated with development of grades III-IV acute GVHD.

DISCUSSION {#S20}
==========

We identified a group of 8 miR biomarkers as potentially being associated with post-transplant mortality risk. Each of these 8 miRs were previously shown to predict the burden of some comorbidities including cardiac, pulmonary, hepatic, renal, autoimmune and rheumatologic comorbidities, as well as psychiatric disease, inflammatory bowel disease, obesity, infection, diabetes, central nervous system disease, and malignancies (for example ([@R15]--[@R34])). While a number miRs were previously shown to predict development of acute GVHD, those miRs were tested after onset of HCT, limiting their use in decision-making before HCT ([@R6]--[@R8]). Here, we used miRs as novel molecular biomarkers of mortality risks but evaluated them before the onset of conditioning regimens. Our results suggest that patients with significant comorbidities might have abnormal expressions of miRs that could be detected before HCT, hence providing a more objective evaluation of comorbidities. We hypothesize that the abnormally expressed miRs set the stage for the development of post-HCT morbidities such as GVHD, infection, and organ failures, as demonstrated in COD, regardless of baseline variables such as characteristics of primary cancer or transplant type.

MiRs are remarkably stable. Tissue-derived miRs can easily reach the circulation where they are readily detectable in a cell-free form, potentially providing a route for minimally invasive detection ([@R35]). Recent data suggest that miRs are actively secreted from cells in 50--90 nm membrane-bound particles called exosomes, which may account for their stability in the bloodstream ([@R36]). This active secretion mechanism may enable the accumulation of miRs in plasma to relatively high levels as compared to other nucleic acid markers (e.g., DNA) that are released only upon cell lysis.

No adjustments were made for multiple comparisons, either in the discovery phase or in the linear regression models, because at this exploratory stage of examination of the studied miRs we were more concerned with type-II errors than type-I errors. Therefore, results should be confirmed in a larger study. Moreover, we showed only that these miRs had differential expression among low- vs. high-risk groups, and these groups were defined based on having an HCT-CI of 0 and surviving (low-risk group) or having an HCT-CI of 4 or more and dying (high-risk group). In this sense, these groups were chosen to be at the extremes, so that if an association between miR and outcome exists, looking at the extreme groups would provide the best chance of identifying a potential signal. The current results, therefore, provide a list of miRs that are merely candidates and that deserve further exploration in a study that does not restrict the population based on HCT-CI and/or outcome.

The previous limitations not withstanding, our results are novel and have significant clinical and scientific applications. Development of a MiR-based measure of health status in a new prospective study could improve our ability of accurate detection of relevant organ dysfunctions prior to HCT and early prediction of HCT-related morbidity and mortality. Information could be used to better determine patient eligibility for transplants and for different conditioning intensity, to assign patients to trials investigating interventions that could alleviate the burden of pre-HCT organ dysfunctions, and to decrease the risk of a given HCT-related complication.
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![Agglomerative cluster "heat-map" analysis of 8 samples from high-risk and 8 samples from low-risk groups. The analysis shows differential under-expression of 7 and differential over-expression of 12 miRs between the two groups.](nihms-1506655-f0001){#F1}

###### 

Patient Characteristics

                            Low Risk   High Risk
  ------------------------- ---------- -----------
  Age                                  
   Mean (years)             48         50
   Range (years)            22--70     24--68
   \< 60 years              72.2%      77.8%
   \> 60 years              27.8%      22.2%
  Gender                               
   Male                     50.0%      50.0%
   Female                   50.0%      50.0%
  Race                                 
   White                    88.9%      83.3%
   Multiple                 0.0%       5.6%
   Unknown                  11.1%      0.0%
   Asian                    0.0%       11.1%
   Black                    0.0%       0.0%
  Ethnicity                            
   Not Hispanic or Latino   100.0%     83.3%
   Hispanic or Latino       0.0%       11.1%
   Unknown                  0.0%       5.6%
  HCT-CI                               
   Mean HCT-CI              0          5.5
   HCT-CI Range             0          4--9
   0                        100.0%     \-
   4                        \-         44.4%
   5 to 6                   \-         27.8%
   7+                       \-         27.8%
  Disease                              
   AML                      77.8%      66.7%
   ALL                      22.2%      33.3%
  Conditioning regimen                 
   RIC/NMA                  50.0%      61.1%
   High                     50.0%      38.9%
  Disease risk index                   
   Low                      0.0%       0.0%
   Intermediate             94.4%      72.2%
   High                     5.6%       27.8%
   Very High                0.0%       0.0%

###### 

Fold change of miR expressions comparing high versus low risk groups

  ------------------------------
  miR-        Fold\    P-value
              change   
  ----------- -------- ---------
  18a         −2.01    0.071

  374b        −2.38    0.039

  484         −1.59    0.085

  374a        −1.62    0.058

  106a + 17   −2       0.099

  454         −2.38    0.039

  520e        −2.72    0.064

  590--3p     2.49     0.008

  590--5p     4.69     0.047

  148b        1.33     0.082

  191         1.57     0.011

  15b         1.5      0.019

  25          1.36     0.08

  142--3p     1.81     0.05

  29c         1.48     0.039

  148a        1.47     0.051

  1308        3.19     0.014

  424         3        0.031

  199b--5p    2.3      0.036
  ------------------------------

###### 

Multivariate analyses, area under the curve (AUC) and odds ratio evaluations of miR expressions between high- and low-risk groups.

  ------------------------------------------------------------------------------------------------------------------------------
  miR-      Difference   95% CI             P-value   Effect\   AUC                 Odds\
                                                      Size                          Ratio
  --------- ------------ ------------------ --------- --------- ------------------- --------------------------------------------
  142--3p   −40,199      −77,907 to −2491   .05       2.09      0.74 (0.58--0.91)   0.15 (0.03--0.87)

  191       −407         −728 to −86        .02       2.49      0.81 (0.66--0.96)   0[\*](#TFN2){ref-type="table-fn"}

  374b      56           8 to 105           .03       2.27      0.75 (0.59--0.92)   9.12 (1.47--56.68)

  424       −31          −59 to −3          .04       2.19      0.76 (0.60--0.92)   0.16 (0.03--0.84)

  454       24           2 to 45            .04       2.17      0.74 (0.58--0.91)   Infinite[\*\*](#TFN3){ref-type="table-fn"}

  590--3p   −5           −9 to −1           .03       2.24      0.75 (0.59--0.92)   0.14 (0.02--0.79)

  15b       −1266        −2492 to −40       .05       2.02      0.74 (0.58--0.91)   0.29 (0.07--1.30)

  29c       −672         −1242 to −102      .03       2.31      0.76 (0.60--0.92)   0.19 (0.04--0.93)
  ------------------------------------------------------------------------------------------------------------------------------

Adjusted mean difference in miR expression between high- and low-risk groups (with 95% confidence interval, p-value), effect size of difference (number of standard-deviation units adjusted difference is away from zero), AUC for expression (95% CI), and odds ratio (95% CI) for low risk between high and low expression.

Eight of 8 low-expression patients were in low-risk category compared to 10 of 28 high-expression patients

Seven of 7 high-expression patients were in low-risk category compared to 11 of 29 low-expression patients
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